These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2957983)

  • 1. Cyclophosphamide 'pulses' in chronic progressive multiple sclerosis. A preliminary clinical trial.
    Myers LW; Fahey JL; Moody DJ; Mickey MR; Frane MV; Ellison GW
    Arch Neurol; 1987 Aug; 44(8):828-32. PubMed ID: 2957983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of clinical and immunologic states in multiple sclerosis.
    Mickey MR; Ellison GW; Fahey JL; Moody DJ; Myers LW
    Arch Neurol; 1987 Apr; 44(4):371-5. PubMed ID: 2950845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of cyclophosphamide on T lymphocytes and T lymphocyte subsets in patients with chronic progressive multiple sclerosis.
    Brinkman CJ; Nillesen WM; Hommes OR
    Acta Neurol Scand; 1984 Feb; 69(2):90-6. PubMed ID: 6231801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunology of multiple sclerosis.
    Oger J; Roos R; Antel JP
    Neurol Clin; 1983 Aug; 1(3):655-79. PubMed ID: 6209537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients. Effects of long-term treatment on immunologic parameters.
    Moody DJ; Kagan J; Liao D; Ellison GW; Myers LW
    J Neuroimmunol; 1987 Mar; 14(2):161-73. PubMed ID: 3818941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Behavior of T lymphocytes, T helper and T suppressor, in multiple sclerosis. Preliminary report].
    Tilbery CP; Lima JG; Scheinberg MA; Santos LM; Yamada FT
    Rev Paul Med; 1984; 102(4):181-3. PubMed ID: 6240108
    [No Abstract]   [Full Text] [Related]  

  • 7. [Indicators of cellular immunity in patients with multiple sclerosis].
    Dziuba AN; Frolov VM; Gaĭdash IS
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(2):12-4. PubMed ID: 1326155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment.
    Moody DJ; Fahey JL; Grable E; Ellison GW; Myers LW
    J Neuroimmunol; 1987 Mar; 14(2):175-82. PubMed ID: 2950131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A longitudinal study of T cell subset surface antigen expression in multiple sclerosis.
    Paty DW; Kastrukoff LF
    Prog Clin Biol Res; 1984; 146():119-24. PubMed ID: 6232622
    [No Abstract]   [Full Text] [Related]  

  • 10. T lymphocyte populations in multiple sclerosis.
    Rodeck U; Kuwert E; Scharafinski HW; Lehmann HJ
    Eur Arch Psychiatry Neurol Sci; 1985; 235(2):119-21. PubMed ID: 2933259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of immunosuppressive agents and particularly of cyclophosphamide on lymphocytes subsets in treated multiple sclerosis patients.
    Gonsette RE; Defalque A; Demonty L
    Riv Neurol; 1987; 57(3):181-4. PubMed ID: 2960008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction of circulating suppressor inducer T lymphocytes in the exacerbation phase of remitting-relapse multiple sclerosis.
    Cafaro A; Spadaro M; Pandolfi F; Tilia G; Scarselli E; Liberati F; Aiuti F
    Riv Neurol; 1987; 57(3):159-62. PubMed ID: 2960006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunosuppressive treatment of multiple sclerosis.
    Schweitzer SF
    J Neurosurg Nurs; 1985 Aug; 17(4):256-9. PubMed ID: 2993548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.
    Crockard AD; McNeill TA; McKirgan J; Hawkins SA
    J Neurol Neurosurg Psychiatry; 1988 Jan; 51(1):139-41. PubMed ID: 2965217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of cyclophosphamide 'pulses' in multiple sclerosis: a prospective study in a clinical cohort.
    Portaccio E; Zipoli V; Siracusa G; Piacentini S; Sorbi S; Amato MP
    Mult Scler; 2003 Oct; 9(5):446-50. PubMed ID: 14582767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease of CD4+CD45+ T-cells in chronic-progressive multiple sclerosis.
    Zaffaroni M; Rossini S; Ghezzi A; Parma R; Cazzullo CL
    J Neurol; 1990 Feb; 237(1):1-4. PubMed ID: 1969461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of immunoregulatory cells and natural killers in the pathogenesis of multiple sclerosis].
    Tunkel' OI; Saidov MZ; Cheredeev AN; Koval'chuk LV; Skriabina EG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(6):880-5. PubMed ID: 6224384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
    Comabella M; Balashov K; Issazadeh S; Smith D; Weiner HL; Khoury SJ
    J Clin Invest; 1998 Aug; 102(4):671-8. PubMed ID: 9710434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid.
    Chofflon M; Weiner HL; Morimoto C; Hafler DA
    Ann Neurol; 1989 May; 25(5):494-9. PubMed ID: 2528316
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Functional properties of T-lymphocytes in patients with multiple sclerosis].
    Zleleznova TA; Ierusalimskiĭ AP
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1989; 89(7):19-23. PubMed ID: 2529722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.